With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Spring has finally sprung in Washington, DC! And that also means a series of substantive discussions on today's most pressing global development issues—from private sector financing in Africa to the future of the World Bank—are springing up at the Center for Global Development. Join us next week in person or online for these important conversations that will happen alongside the World Bank and IMF Spring Meetings.
In December 2018, the Gavi Alliance hosted a mid-term review to assess progress towards its core purpose: “reach every child everywhere with vaccines against preventable diseases.” The good news is that there’s been advances on new vaccine introductions, and an estimated 65 million children were immunized with Gavi-supported new and underutilized vaccines in 2017. The bad news? There is still huge variability on the measure that counts most for building herd immunity and reducing vaccine-preventable disease: full vaccination for age among children under 2 years old.
Country efforts on the SDGs since 2015 are off-track, say Amanda Glassman and Liesl Schnabel. As the second UN Data Forum kicks off in Dubai, they call for a greater focus on the completeness, accuracy, and availability of data.
It’s been three years since the rollout of the DREAMS program began, and earlier this month in collaboration with the Population Council, CGD convened key players to discuss emerging results, what they mean for the future of DREAMS, and how we can ensure that the next years of programming go even farther to deliver the most effective services to those most at risk.
Women’s equality and empowerment is a driver of economic growth and development around the world, and development organizations routinely include and espouse this goal as part of their missions and activities. But if you peel back the curtain, there are serious questions about whether—behind the scenes—development organizations are living up to these values in the workplace.
Here at CGD, we’re always working on new ideas to stay on top of the rapidly changing global development landscape. Whether it’s examining new technologies with the potential to alleviate poverty, presenting innovative ways to finance global health, assessing changing leadership at international institutions, or working to maximize results in resource-constrained environments, CGD’s experts are at the forefront of practical policy solutions to reduce global poverty and inequality. Get an in-depth look below at their thoughts on the 2018 global development landscape.
My recent blog post on economics at WHO alongside Tony Culyer’s open letter to incoming Director-General Dr. Tedros generated great feedback and discussion. Below, you can find my views on some of the key points made, as well as WHO health economist Melanie Bertram’s response to the letter here.
Kellyanne Conway called him a “man of action” after a whirlwind first week in which President Trump signed 14 Executive Orders and presidential memoranda, covering most of his key campaign issue areas from health to immigration to trade. In a series of blogs, CGD experts have been examining how some of these specific policy intentions could impact development progress. As you would expect from a group of economists, we believe in—and encourage—evidence-based policymaking, and here we look at what the existing evidence and research tell us about how likely these Executive Orders are to achieve the president’s stated goals.
I’m very pleased to announce the addition of Stephen T Isaacs to the Center for Global Development’s Board of Directors. Steve has been a leader in the biomedical field for over 30 years, founding companies that focus on developing novel, innovative immunotherapies and vaccines for cancer and infectious diseases. He is the Chairman, Director, President, and Chief Executive Officer of Aduro Biotech.